ECSS
ALNY icon

Eurizon Capital SGR SpA’s Alnylam Pharmaceuticals ALNY Stock Holding History

Eurizon Capital SGR SpA’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.83M Sell
22,698
-1,486
-6% -$448K 0.02% 381
2026
Q1 		$7.96M Sell
24,184
-226
-0.9% -$76.9K 0.02% 359
2025
Q4 		$9.71M Buy
+24,410
New +$10.8M 0.03% 293

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's ALNY Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.1% in Q2 2026, selling an estimated $448K and leaving 22,698 shares worth $6.83M. The position accounts for 0.02% of the portfolio, ranked #381.

Eurizon Capital SGR SpA first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.71M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Eurizon Capital SGR SpA held 22,698 shares of Alnylam Pharmaceuticals worth $6.83M as of Q2 2026.
  • Eurizon Capital SGR SpA sold 1,486 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $448K.
  • Alnylam Pharmaceuticals made up 0.02% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #381 holding.
  • Eurizon Capital SGR SpA first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Alnylam Pharmaceuticals position peaked at $9.71M in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.